IL-2 and IL-15 augment HBV therapeutic vaccination and PD1 blockade for functional cure in the AAV-HBV mouse model
In mice with very high levels of HBsAg (10<sup>4</sup>-10<sup>5</sup> IU/mL), levels that are observed clinically during standard HBV therapy and that were brought low (10<sup>2</sup> IU/mL) by HBV siRNA pre-treatment prior to therapeutic vaccination, PDL1 blockade in combination with stabilized cytokines IL-2 or IL-15 led to immune control of HBsAg in vaccinated animals.
Authors
- Jenaya Hooks
- George Kukolj
- Haoyuan Liu (ORCID: https://orcid.org/0000-0001-8728-332X)
- Craig S. Pace
- Sonam Popli (ORCID: https://orcid.org/0000-0001-7450-6862)
- Gavin Lewis
- Kirsten Malo
- Thomas Rowland
Institutions
- Johnson & Johnson (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1562107
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Janssen Research and Development